Spatial transcriptomics

Spatial OMICS Market Research Report 2023 - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 27, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Spatial transcriptomics, DNA, Chemistry, Gene, Proteomics, Disease, Tissue, Genomics, USD, OMICS, COVID-19, Biomedical Research, Growth, FASP, Workflow, Government, OMIC, RNA, Medical imaging

The "Spatial OMICS Market Size, Share, & Trends Analysis Report By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics), By Product, By Workflow, By Sample Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spatial OMICS Market Size, Share, & Trends Analysis Report By Technology (Spatial Transcriptomics, Spatial Genomics, Spatial Proteomics), By Product, By Workflow, By Sample Type, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global spatial OMICS market size is expected to reach USD 558.0 million by 2030.
  • The spatial OMICS field originated from hyperplexed imaging; however, key players have shifted toward the development of spatial transcriptomics solutions and products.
  • The development of novel technologies for spatial OMICS is anticipated to create lucrative opportunities for the fields of translational research as well as diagnostics.

South Korean Biotech Company Portrai Inc. Adopts Infortrend Storage to Enable AI Data Analysis for Pharmaceutical Drug Development

Retrieved on: 
Tuesday, September 12, 2023
Cloud, Spatial transcriptomics, NL-SAS, TB, Research, RNA, TWSE, JBOD, Infortrend, AI, Daou Technology Inc., Medical imaging, Mental illness portrayed in media

TAIPEI, Sept. 12, 2023 /PRNewswire/ -- Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage manufacturer, provided South Korean biotech company Portrai Inc. with EonStor GS enterprise unified storage solution to enable their innovative research technology combining AI and RNA analysis for pharmaceutical drug development.

Key Points: 
  • TAIPEI, Sept. 12, 2023 /PRNewswire/ -- Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage manufacturer, provided South Korean biotech company Portrai Inc. with EonStor GS enterprise unified storage solution to enable their innovative research technology combining AI and RNA analysis for pharmaceutical drug development.
  • The company uses the unique combination of AI and Spatial Transcriptomics aiming to revolutionize pharmaceutical drug development.
  • This analysis technology continuously generates data ranging from 10GB to 1TB for an image sized 1cm2, which requires storage space.
  • "In the course of pharmaceutical drug development, Spatial Transcriptomics and AI analysis generate massive amounts of data.

South Korean Biotech Company Portrai Inc. Adopts Infortrend Storage to Enable AI Data Analysis for Pharmaceutical Drug Development

Retrieved on: 
Tuesday, September 12, 2023
Cloud, Spatial transcriptomics, NL-SAS, TB, Research, RNA, TWSE, JBOD, Infortrend, AI, Daou Technology Inc., Medical imaging, Mental illness portrayed in media

TAIPEI, Sept. 12, 2023 /PRNewswire/ -- Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage manufacturer, provided South Korean biotech company Portrai Inc. with EonStor GS enterprise unified storage solution to enable their innovative research technology combining AI and RNA analysis for pharmaceutical drug development.

Key Points: 
  • TAIPEI, Sept. 12, 2023 /PRNewswire/ -- Infortrend® Technology, Inc. (TWSE: 2495), the industry-leading enterprise storage manufacturer, provided South Korean biotech company Portrai Inc. with EonStor GS enterprise unified storage solution to enable their innovative research technology combining AI and RNA analysis for pharmaceutical drug development.
  • The company uses the unique combination of AI and Spatial Transcriptomics aiming to revolutionize pharmaceutical drug development.
  • This analysis technology continuously generates data ranging from 10GB to 1TB for an image sized 1cm2, which requires storage space.
  • "In the course of pharmaceutical drug development, Spatial Transcriptomics and AI analysis generate massive amounts of data.

Global Spatial Genomics & Transcriptomics Global Market Report 2023: Increasing Adoption of Spatial Genomics & Transcriptomics Analysis in Translational Research to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Software, Technology, Pharmaceutical, Health, Government, Cancer, Science and technology in Asia, Drug discovery, Research, End user, Biomarker, USD, Regenerative medicine, Neoplasm, Growth, Conditional sentence, Incidence, Spatial transcriptomics, Neurodegeneration, Translational research, Medicinal plants, Software

The "Global Spatial Genomics & Transcriptomics Market by Technique (Spatial Transcriptomics, Spatial Genomics), Product (Instruments, Consumables, Software), Application (Translational Research, Drug Discovery), End User, Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Spatial Genomics & Transcriptomics Market by Technique (Spatial Transcriptomics, Spatial Genomics), Product (Instruments, Consumables, Software), Application (Translational Research, Drug Discovery), End User, Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Market growth is largely driven by the shift from strictly research applications to drug discovery & development for areas such as neurodegenerative diseases and cancer.
  • Spatial genomics and transcriptomics are also anticipated to address current unmet clinical needs in oncology, including the demand for predictive biomarkers of response.
  • Based on application, the spatial genomics and transcriptomics market is categorized into translational research and drug discovery & development.

Spatial Genomics, Transcriptomics and Proteomics Solutions Market Report 2022: Demand from Life Science Research Sector Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Software, Technology, Biotechnology, Health, NGS, Protein, Real-time, Severe acute respiratory syndrome coronavirus 2, Spatial analysis, Patient, Cell, Proteomics, JAMA Oncology, RNA, Mass spectrometry, Whole genome sequencing, Disease, Partnership, Flow cytometry, Growth, Senior, Gene, DNA, Proteome, Publication, Transcriptome, ELISA, Spatial transcriptomics, Immunohistochemistry, Type, Research, Nature Methods, Genome, Biomarker, Renewable energy, Marketing, Microscope, Medical imaging, Online shopping, Real estate, USD

The report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the spatial omics solutions market.

Key Points: 
  • The report offers an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the spatial omics solutions market.
  • In fact, according to a recent survey, approximately 44% of respondents expressed their intent to purchase a spatial profiling platform.
  • A detailed assessment of the current market landscape of the spatial genomics, transcriptomics and proteomics solutions.
  • Which companies are actively filing patents to drive innovation in spatial omics solutions market?

Oxford Nanopore Technologies Announces New Collaboration With 10x Genomics to Make Single-cell and Spatial Full-length Isoform Transcript Sequencing Accessible to Any Laboratory

Retrieved on: 
Thursday, October 27, 2022
Health, Technology, Other Technology, Genetics, Other Health, Biotechnology, Genomics, Cell biology, Embryonic development, Alternative splicing, Oxford Nanopore Technologies, Chromium, Spatial transcriptomics, Oxford, Scanning Flow Cell, DNA, CPP, Population, Genetics, Nanopore sequencing, Biology, Workflow, Nanopore, 10x Genomics, Research, Transcriptome, Atlas, USD, B cell, Antibiotics, Medical imaging

Oxford Nanopore Technologies plc (Oxford Nanopore) today announces a collaboration with 10x Genomics, to enable a streamlined workflow for sequencing full-length transcripts in single reads on highly accessible Oxford Nanopore devices.

Key Points: 
  • Oxford Nanopore Technologies plc (Oxford Nanopore) today announces a collaboration with 10x Genomics, to enable a streamlined workflow for sequencing full-length transcripts in single reads on highly accessible Oxford Nanopore devices.
  • The collaboration covers the addition of Oxford Nanopores PromethION devices and selected consumables, in conjunction with sample preparation on the 10x Genomics devices, into the 10x Genomics Compatible Partner Program (CPP).
  • Both parties believe this will enable a streamlined customer experience and highlight the compelling utility of nanopore-based sequencing in conjunction with 10x Genomics workflows.
  • Now, with Oxford Nanopore, 10x Genomics users can easily add a new dimension to their data using the fastest and most cost-effective full-length transcript sequencing approach.

IDEX Health & Science Releases BioLine™ CMOS Camera to Advance Imaging Capabilities

Retrieved on: 
Tuesday, May 10, 2022
List of life sciences, FLI, LLC, CMOS, Bioline, Microfluidics, Partnership, DNA sequencing, SNR, Health, Spatial transcriptomics, Life, IDEX, Solution, CCD, Technology, Camera, Medical imaging, Sony

ROCHESTER, N.Y., May 10, 2022 /PRNewswire-PRWeb/ -- IDEX Health & Science is launching a new CMOS camera platform developed in-house by Finger Lakes Instrumentation (FLI), acquired by IDEX in 2018. The BioLine™ CMOS platform was designed to support a range of Sony sensors with various pixel densities and formats for Life Science applications such as Gel Doc Imaging, DNA Sequencing, and Spatial Transcriptomics. This line of cameras also offers a path for life science instrumentation manufacturers looking to transition from increasingly obsolete CCD sensors.

Key Points: 
  • ROCHESTER, N.Y., May 10, 2022 /PRNewswire-PRWeb/ -- IDEX Health & Science is launching a new CMOS camera platform developed in-house by Finger Lakes Instrumentation (FLI), acquired by IDEX in 2018.
  • The BioLine CMOS platform was designed to support a range of Sony sensors with various pixel densities and formats for Life Science applications such as Gel Doc Imaging, DNA Sequencing, and Spatial Transcriptomics.
  • Join the IDEX Health & Science team for a webinar on June 20, 2022 focused on leveraging all the benefits of CMOS technology and making a data-driven decision for camera selection.
  • About IDEX Health & Science, LLC
    IDEX Health & Science, LLC is the global leader in life science fluidics, microfluidics, and optics, offering a three-fold advantage to customers by bringing optofluidic paths to life with strategic partnerships, solutions, and expertise.

BioChain announces partnership with Nanostring to provide Spatial Multiomics Services

Retrieved on: 
Tuesday, April 26, 2022
Protein, Drug development, IRB, DNA, OEM, NanoString Technologies, CLIA, Spatial transcriptomics, Molecular biology, RNA, Drug discovery, Business, Patient, Cell, Tissue, Business development, Cancer, Medical imaging

NEWARK, Calif., April 26, 2022 /PRNewswire/ --BioChain Institute, ("BioChain") a leader in high-quality processed bio-sample products is excited to adopt GeoMx platform to provide digital spatial profiling services.

Key Points: 
  • NEWARK, Calif., April 26, 2022 /PRNewswire/ --BioChain Institute, ("BioChain") a leader in high-quality processed bio-sample products is excited to adopt GeoMx platform to provide digital spatial profiling services.
  • Scientists at BioChain have undergone comprehensive training and evaluation byteam of scientific experts and are now fully equipped to deliver high quality spatial multiomics services.
  • Spatial transcriptomics and spatial proteomics have been termed the "new frontier" in molecular biology due to the enormous promise of new discoveries and diagnostics.
  • BioChain has been the leading front in providing human and animal tissues for over 20 years as well as histopathology services.

NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference

Retrieved on: 
Friday, April 8, 2022
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Adoption, Radiation, NASDAQ, Proteogenomics, Translational medicine, National Health, Gene expression, Squamous cell carcinoma, Biopsy, NHMRC, ER, HER2, Patient, IHC, RNA, PR, AACR, Research, Proteome, NanoString Technologies, SMI, American Association, Cancer, Atlas, CEO, Laboratory, 2021 Essex County Council election, Association, Biology, Spatial transcriptomics, Protein, Medical Research Council, National Health and Medical Research Council, MicroRNA, CST, COVID-19, Gene, Melanoma, Chemistry, Phenotype, Transcriptome, DSP, Breast cancer, American Association for Cancer Research, WTA, Pancreatic cancer, Nextgen, Large-cell lung carcinoma, Pharmaceutical industry, Microscope, Medical imaging, BC, Technology

This is the largest number of AACR abstracts in a single year for NanoString and demonstrates the increasing adoption of spatial biology in cancer research.

Key Points: 
  • This is the largest number of AACR abstracts in a single year for NanoString and demonstrates the increasing adoption of spatial biology in cancer research.
  • NanoString customers continue to make tremendous contributions to our understanding of cancer and the development of cures, said Brad Gray, president and CEO of NanoString.
  • We are particularly excited to highlight research studies that leverage our latest product offerings in spatial biology.
  • NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year

Retrieved on: 
Wednesday, December 1, 2021
Gene expression, Single cell, Microfluidics, Security (finance), Disclosure, Spatial analysis, Cell, Neuroscience, Technology, Time, Publication, Acquisition, Biology, Genomics, Health, ATAC, Chromium, Regulation, R&D, U.S. Securities and Exchange Commission, Chromatin, Nature, Spatial transcriptomics, Software, Research, Entrepreneurship, Assay, Infection, Patent, Culture, Social media, Efficiency, Immune system, B cell, Scientist, Regulation Fair Disclosure, Fine chemical, Vaccine

This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.

Key Points: 
  • This recognition marks the fifth consecutive year that a 10x Genomics product made the list, with a total of seven products appearing as Top 10 Innovations since 2015.
  • "We're honored and humbled to be consistently recognized by The Scientist for our culture of innovation and strong cadence of technological advancement.
  • To see the full list of The Scientist's 2021 Top 10 Innovations, please visit www.the-scientist.com/features/2021-top-10-innovations-69438 .
  • 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.